Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron Pharmaceuticals following this morning's announcement that the Phase 3 Panorama clinical trial in Eylea met its 24-week primary endpoint in patients with nonproliferative diabetic retinopathy. While investors may continue to worry about Eylea's status among competitors like RTH258, DR represents a "new leg of growth and a key opportunity" for the Eylea franchise, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Regeneron shares with a $500 price target.